Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

This Phase I/II study tests a three-drug combination — pemigatinib (a targeted therapy blocking the FGFR2 gene), atezolizumab (an immunotherapy), and bevacizumab (a drug that cuts off blood supply to tumors) — for advanced bile duct cancer (cholangiocarcinoma) that carries a specific FGFR2 gene fusion, after failure of standard chemotherapy. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic bile duct cancer - Your tumor has an FGFR2 gene fusion or rearrangement confirmed by a validated test - Your cancer has progressed on or you refused/could not tolerate first-line chemotherapy (including gemcitabine-based therapy) - You have at least one measurable tumor - Your overall health is good (ECOG performance status 0–1) - Your blood counts and organ function meet study requirements **You may NOT be eligible if...** - Your cancer has spread to the eye (retinal detachment or other retinal pathology) - You have active autoimmune disease requiring treatment - You have uncontrolled infection or active hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.